ABEO — ABEONA THERAPEUTICS INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 318306 ·
Last close
$2.60
Market Cap
$160.27M
52W High
$7.65
52W Low
$2.09
ADV30
1,911,057
Next earnings
2026-11-09
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 11,380,000 7,203,000 -13,653,000 -20,191,000 179,507,000 56,229,000 51,449,000
Mar 2026 8,720,000 6,024,000 -23,033,000 -17,075,000 198,494,000 61,374,000 53,555,000
Dec 2025 5,420,000 2,583,000 -22,911,000 -20,460,000 219,570,000 78,437,000 60,354,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-63,560,000
Investing CF
$51,907,000
Financing CF
$-5,285,000
CapEx
$-2,786,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-784,149,000
Inventory
$4,664,000
Receivables
$16,213,000
ST Investments
$68,657,000
EBIT TTM
$-59,762,000
Pretax Income TTM
$-62,729,000
Interest Exp TTM
$2,967,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$39,011,000
EBITDA
$-69,675,000
Free Cash Flow
$-47,079,124
Enterprise Value
$19,983,352
Total Cash
$134,940,992
Total Debt
$16,629,000
Shares Out
61,641,223
Trailing EPS
$-1.16
Book Value
$2.20
ROE
-42.1%
ROA
-22.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 5,820,000 -89,448,000 71,183,000 219,570,000 60,354,000 159,216,000 -76,326,000
Dec 2024 0 -64,211,000 -63,734,000 108,931,000 64,900,000 44,031,000 -56,015,000
Dec 2023 3,500,000 -48,200,000 -54,188,000 64,002,000 49,176,000 14,826,000 -37,009,000
Dec 2022 1,414,000 -45,257,000 -39,696,000 64,214,000 37,453,000 26,761,000 -43,483,000

TTM Snapshot

Revenues TTM
$25,520,000
NetIncome TTM
$-62,887,000
OpCashFlow TTM
—
Assets (Latest)
$179,507,000
Forward EPS
$-0.48

Max Pain — expiry 2027-06-17

max pain strike: $2.00 · spot: $2.73 · call oi: 1,560 · put oi: 55
Expected Move to 2027-06-17: ±$1.55 (56.78%) — implied range $1.18 – $4.28 · ATM straddle on $3.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ANTX AN2 Therapeutics, Inc. $160.50M $4.23 —
BCYC BICYCLE THERAPEUTICS PLC $162.10M $3.20 —
PRQR ProQR Therapeutics N.V. $162.29M $1.15 —
YARW Yarrow Bioscience, Inc. $163.04M $14.21 —
BBOT BridgeBio Oncology Therapeutics, Inc. $155.69M $1.94 —

News headlines (Yahoo Finance, 1h cache)

Abeona Therapeutics (ABEO) Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns Grow
2026-11-14 04:21 · Yahoo
ABEO: In-Licenses Phase 3 Candidate for Eosinophilic Esophagitis
2026-11-13 09:01 · Yahoo
Abeona Therapeutics Plans New Phase 3 Trial for ABO-801 as ZEVASKYN Launch Expands
2026-11-12 12:14 · Yahoo
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
2026-11-10 12:30 · Yahoo
Abeona Therapeutics Inc (ABEO) (Q3 2026) Earnings Call Highlights: ZivaSkin Revenue Jumps 18% ...
2026-11-09 23:04 · Yahoo
Abeona Therapeutics Inc. Q3 2026 Earnings Call Summary
2026-11-09 21:44 · Yahoo
Abeona Therapeutics (ABEO) Q3 2026 Earnings Call Transcript
2026-11-09 21:14 · Yahoo
Top Midday Decliners
2026-11-09 18:55 · Yahoo
What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call
2026-11-09 15:14 · Yahoo
Abeona Therapeutics Acquires Eosinophilic Esophagitis Drug Candidate for $20 Million in Stock
2026-11-09 14:09 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-16 8:00:20 2026-11-13 Charles Faith L. Dir P - Purchase 2.29 15000 34349